7. 2024 NICE Guideline: Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. 8. Wang Y, et al. BMC Med. 2024 Mar 26;22(1):142.
Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations Novel Agents/Combinations for aRCC New formulations for current therapies – SC vs. IV Management of Adverse Events – IO/IO and IO/TKI ...